AC
CKPT

Armistice Capital’s Checkpoint Therapeutics CKPT Stock Holding History

Armistice Capital’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,460,545
Closed -$14.3M – 239
2024
Q4 		$14.3M Buy
4,460,545
+574,545
+15% +$1.95M 0.19% 82
2024
Q3 		$8.7M Buy
3,886,000
+1,380,000
+55% +$3.18M 0.14% 100
2024
Q2 		$5.39M Sell
2,506,000
-210,000
-8% -$374K 0.07% 111
2024
Q1 		$5.57M Buy
2,716,000
+290,000
+12% +$578K 0.07% 121
2023
Q4 		$5.56M Buy
2,426,000
+362,000
+18% +$788K 0.08% 120
2023
Q3 		$3.51M Buy
2,064,000
+651,000
+46% +$1.48M 0.05% 120
2023
Q2 		$3.49M Buy
+1,413,000
New +$3.86M 0.05% 128
2023
Q1 		– Sell
-691,895
Closed -$3.54M – 233
2022
Q4 		$3.54M Buy
+691,895
New +$4.98M 0.06% 108

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Armistice Capital's CKPT Position: Q1 2025 in Review

Armistice Capital sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 4,460,545 shares — an estimated $14.3M sold.

Armistice Capital first reported a position in CKPT in Q4 2022 and held it in 8 quarters. The position peaked at $14.3M in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Armistice Capital reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Armistice Capital sold 4,460,545 Checkpoint Therapeutics shares in Q1 2025, an estimated $14.3M.
  • Armistice Capital first reported a position in Checkpoint Therapeutics in Q4 2022 and held it in 8 quarters.
  • Armistice Capital's Checkpoint Therapeutics position peaked at $14.3M in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.